HC Wainwright Issues Positive Forecast for Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Price

Catalyst Pharmaceuticals (NASDAQ:CPRX - Free Report) had its target price boosted by HC Wainwright from $30.00 to $35.00 in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company's stock.

Other equities analysts also recently issued research reports about the stock. Bank of America reaffirmed a "buy" rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday. Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target on the stock. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, January 3rd. Finally, Truist Financial upped their target price on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a report on Monday, November 11th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $32.86.

Catalyst Pharmaceuticals Stock Performance

Shares of Catalyst Pharmaceuticals stock traded down $0.88 on Friday, hitting $21.92. The stock had a trading volume of 2,509,148 shares, compared to its average volume of 1,666,905. The stock has a 50 day moving average of $21.77 and a 200 day moving average of $19.90. The firm has a market capitalization of $2.61 billion, a P/E ratio of 18.58, a PEG ratio of 3.35 and a beta of 0.79. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 12,000 shares of the business's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now owns 51,391 shares in the company, valued at $1,167,603.52. The trade was a 18.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Molly Harper sold 17,500 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 79,500 shares of company stock valued at $1,754,140. 11.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its stake in shares of Catalyst Pharmaceuticals by 9.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,000,756 shares of the biopharmaceutical company's stock worth $46,479,000 after purchasing an additional 263,099 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 130,918.8% during the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company's stock worth $45,968,000 after purchasing an additional 2,965,310 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Catalyst Pharmaceuticals by 15.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company's stock worth $33,702,000 after purchasing an additional 287,300 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Catalyst Pharmaceuticals by 4.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company's stock valued at $23,215,000 after purchasing an additional 50,804 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in shares of Catalyst Pharmaceuticals by 47.9% during the 2nd quarter. Point72 Asset Management L.P. now owns 618,296 shares of the biopharmaceutical company's stock worth $9,577,000 after acquiring an additional 200,370 shares during the period. Institutional investors and hedge funds own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.